Exebacase: A Novel Approach to the Treatment of Staphylococcal Infections

被引:7
|
作者
McCarthy, Matthew W. [1 ]
机构
[1] Weill Cornell Med Coll, 525 East 68th St,Box 130, New York, NY 10065 USA
关键词
AUREUS PNEUMONIA; LYSIN; PURIFICATION; BIOFILMS; THERAPY;
D O I
10.1007/s40268-022-00383-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Lysins are bacteriophage-derived enzymes that degrade essential components of bacteria. Exebacase (Lysin CF-301) is an attractive antimicrobial agent because it demonstrates rapid bacteriolytic activity against staphylococcal species, including Staphylococcus aureus, has a low resistance profile, eradicates biofilms, and acts synergistically with other antibiotics. Combinations including exebacase and standard of care antibiotics represent an alternative to antibiotic monotherapies currently used to treat invasive staphylococcal infections. This manuscript reviews what is known about exebacase and explores how this novel agent may be used in the future to treat human bacterial pathogens.
引用
收藏
页码:113 / 117
页数:5
相关论文
共 50 条